Extensively drug-resistant Haemophilus influenzae - emergence, epidemiology, risk factors, and regimen.

BACKGROUND: Concern about Haemophilus influenzae infection has been increasing over recent decades. Given the emergence of H. influenzae with severe drug resistance, we assessed the prevalence of as well as risk factors and potential therapies for extensively drug-resistant (XDR) H. influenzae infection in Taiwan. RESULTS: In total, 2091 H. influenzae isolates with disk diffusion-based antibiotic susceptibility testing from 2007 to 2018 were enrolled. H. influenzae strains resistant to ampicillin, chloramphenicol, levofloxacin, and trimethoprim-sulfamethoxazole tended to be isolated from patient wards (≧41%), whereas those resistant to amoxicillin-clavulanate, cefotaxime, and cefuroxime were more likely to be isolated from intensive care units (approximately 50%). XDR H. influenzae was first identified in 2007, and its incidence did not significantly change thereafter. Overall prevalence of single, multiple, and extensively drug-resistant H. influenzae over 2007-2018 was 21.5% (n = 450), 26.6% (n = 557), and 2.5% (n = 52), respectively. A stepwise logistic regression analysis revealed that blood culture (odds ratio: 4.069, 95% confidence intervals: 1.339-12.365, P = 0.013) was an independent risk factor for XDR H. influenzae infection. No nosocomial transmission of XDR H. influenzae observed. Antibiotic susceptibility testing results demonstrated that cefotaxime was effective against 78.8% (n = 41) of the XDR strains. CONCLUSIONS: The presence of XDR H. influenzae strains was identified in Taiwan, and cefotaxime was efficacious against most of these strains.

Comparison of the Vitek MS and Bruker Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Systems for Identification of Chryseobacterium Isolates from Clinical Specimens and Report of Uncommon Chryseobacterium Infections in Humans.

Matrix-assisted laser desorption ionization-time of flight mass spectrometry is becoming more popular and is replacing traditional identification methods in the clinical microbiology laboratory. We aimed to compare the Vitek mass spectrometry (MS) and Bruker Biotyper systems for the identification of Chryseobacterium isolated from clinical specimens and to report uncommon Chryseobacterium infections in humans. The microbial database from a hospital was searched for records between 2005 and 2016 to identify cultures that yielded Chryseobacterium Species identification by the Vitek MS and Bruker Biotyper systems was compared to identification by 16S rRNA gene sequencing. Over the study period, 140 Chryseobacterium isolates were included. Based on 16S rRNA gene sequencing, 78 isolates were C. indologenes, 39 were C. gleum, 12 were uncommon Chryseobacterium species (C. arthrosphaerae, C. culicis, C. cucumeris, C. bernardetii, C. artocarpi, and C. daecheongense), and the remaining 11 isolates were only identified at the genus level. The Vitek MS and Bruker Biotyper systems correctly identified 98.7% and 100% of C. indologenes isolates, respectively. While the Bruker Biotyper accurately identified 100% of C. gleum isolates, the Vitek MS system correctly identified only 2.6% of isolates from this species. None of the uncommon Chryseobacterium species were successfully identified by either of these two systems. The overall accuracies of Chryseobacterium identification at the species level by the Vitek MS and Bruker Biotyper systems were 60.5% and 90.7%, respectively. An upgrade and correction of the Vitek MS and Bruker Biotyper databases is recommended to correctly identify Chryseobacterium species.

Comparison of four automated microbiology systems with 16S rRNA gene sequencing for identification of Chryseobacterium and Elizabethkingia species.

Chryseobacterium and Elizabethkingia species have recently emerged as causative agents in life-threatening infections in humans. We aimed to evaluate the rates at which four common microbial identification systems identify Chryseobacterium and Elizabethkingia species in clinical microbiology laboratories. Based on the results of 16S rRNA gene sequencing, a total of 114 consecutive bacteremic isolates, including 36 (31.6%) C. indologenes, 35 (30.7%) E. anophelis, 22 (19.3%) C. gleum, 13 (11.4%) E. meningoseptica, and other species, were included in this study. The overall concordance between each method and 16S rRNA gene sequencing when identifying Chryseobacterium and Elizabethkingia species was 42.1% for API/ID32, 41.2% for Phoenix 100 ID/AST, 43.9% for VITEK 2, and 42.1% for VITEK MS. Among the 22 C. gleum isolates, only one (4.8%) was correctly identified using VITEK 2 and Phoenix 100 ID/AST, and none were accurately recognized using API/ID32 or VITEK MS. Except for two isolates that were not identified using API/ID32, all E. anophelis isolates were misidentified by all four identification systems as E. meningoseptica. Our results show that these approaches have low accuracy when identifying Chryseobacterium and Elizabethkingia species. Hence, we recommend amending the discrimination rate of and adding non-claimed pathogens to databases of microbial identification systems.

Bacterial colonization patterns in daily chlorhexidine care at the exit site in peritoneal dialysis patients-A prospective, randomized controlled trial.

Bacterial colonization patterns in daily chlorhexidine care at the exit site in peritoneal dialysis (PD) patients were not known. We performed a prospective, randomized controlled trial enrolling 89 PD patients. After stratification by initial Staphylococcus aureus (SA) carrier status, patients were randomly assigned to receive daily 4% chlorhexidine care (intervention group) or normal saline (control group) at the exit site. Monthly, we cultured bacteria from the exit site and nasal swabs for 1 year. The SA colonization rates at exit site at 6 and 12 months were significantly lower in the intervention group than the control group (5.0% vs. 22.9%, p = 0.023 and 8.6% vs. 28.1%, p = 0.037 for 6 and 12 months, respectively). The Methicillin-resistant SA (MRSA) colonization rate at exit site at 6 months was similar (5.7% vs. 2.5%,p = 0.596) in control and intervention group, but significantly lower in the intervention group than the control group at exit site at 12months (0% vs. 12.5%, p = 0.047). The gram-negative bacilli (GNB) colonization rates were similar between the intervention and control groups at 6 and 12 months. Genotyping of all MRSA isolates showed ST (sequence type) 59 was the most predominant clone. In conclusion, chlorhexidine care at the exit site in PD patients may be a good strategy for SA and MRSA decolonization. TRIAL REGISTRATION: ClinicalTrials.gov NCT02446158.

Urinary Mycobacterium szulgai infection in an immunocompetent patient.

Mycobacterium szulgai is one of the nontuberculous mycobacteria (NTM) and rarely causes diseases in human beings, particularly in immunocompetent patients. Less than 1% of all cases of NTM infection are caused by M szulgai, but the incidence is continuously increasing. Although extrapulmonary infections have been reported, most M szulgai infections are associated with pulmonary diseases. However, to our knowledge, a urinary tract infection caused by M szulgai has never before been reported. Here we report an immunocompetent female who experienced a urinary tract infection caused by M szulgai and was successfully treated with 4 months of isoniazid, rifampin, and levofloxacin.

Indigenous case of disseminated histoplasmosis, Taiwan.

We report the first indigenous case of disseminated histoplasmosis in Taiwan diagnosed by histopathology of bone marrow, microbiologic morphology, and PCR assay of the isolated fungus. This case suggests that histoplasmosis should be 1 of the differential diagnoses of opportunistic infections in immunocompromised patients in Taiwan.